Cuba Talks Parkinson Disease Prensa Latina, Cuba - ... de Restauracion Neurologica (CIREN), a 13-year world pioneer in selective subtalamotomy, so far the most efficient treatment for Parkinson?s disease. ...
Don?t Fire Until You See the Whites of Their Eyes The Epoch Times, NY - It affects close to 300000 Canadians, more Canadians than those who have breast cancer, prostate cancer, Parkinson?s disease, and Alzheimer?s disease...
Biotech faces a bitter season Austin American-Statesman, TX - ... moved to smaller offices to conserve the $6.5 million it has on hand; and is delaying research on drugs for Alzheimer's disease and Parkinson's disease, ...
Gala evening at the movies Mirror, MI - Western Oakland Parkinson Support Group meets 709 pm on the second Tuesday of the month except January, July and August, at Farmington Hills Baptist Church, ...
Ask Dr. Gott: B-50 possible treatment for the shakes Monterey County Herald, CA - Nov 23, 2008 To give you related information, I am sending you a copy of my health report "Parkinson's Disease." Other readers who would like a copy should send a ...
Source: Google News
Recent News and Articles on the Keywords: web + 0.22 + dementia Related to the article below (Last Update: 8/5/2008)
Learning Tree Announces Third Quarter 2008 Results MarketWatch - Learning Tree develops, markets and delivers a broad, proprietary library of instructor-led courses focused on Web development, operating systems, ...LTRE
AtriCure Reports Record Second Quarter 2008 Financial Results PR Newswire (press release), NY - A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at http://www.atricure.com ...ATRC
Salix Pharmaceuticals Reports 2Q2008 Results FOXBusiness - Aug 4, 2008 Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at www.salix.com. A replay of the web...SLXP
Henry Schein Reports Record Second Quarter Results Trading Markets (press release), CA - Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. ...HSIC
Overview of clinical trials of hydergine in dementia - LS Schneider, JT Olin - Archives of Neurology, 1994 - Am Med Assoc ...Web browser does not support basic Web standards. ... neuropsychological measures (d =
0.27; 95% CI, 0.22 to 0.32 ... 4 mg or more, and vascular dementia were generally ...
Dementia and psychopathology among individuals with mental retardation EJ Wade - 2005 - gradworks.umi.com ... in predicting the presence or absence of dementia by the ... to 0.27, but decreased adjusted
R 2 from 0.22 to 0.21 ... 1. Start by searching the library's Web site for ... -
Cognitive Loss in Dementia With Lewy Bodies and Alzheimer Disease - T Shimomura, E Mori, H Yamashita, T Imamura, N … - Archives of Neurology, 1998 - Am Med Assoc ...Web browser does not support basic Web standards. ... of Neuropsychological Test Scores
Between Probable Dementia With Lewy ... R block design (partial r 2 =0.22, F 1 ...
Dementia With Lewy Bodies and the Neurobehavioral Decline of Mervyn Peake - DJ Sahlas - Archives of Neurology, 2003 - Am Med Assoc ... your Web browser does not support basic Web standards. ... of cortical Lewy bodies in
cases of dementia was firmly ... 0.87-1.00) but lower sensitivities (0.22-0.89). ...
Specific cognitive deficits in mild frontal variant frontotemporal dementia - S Rahman, BJ Sahakian, JR Hodges, RD Rogers, TW … - Brain, 1999 - Oxford Univ Press ... Specific cognitive deficits in mild frontal variant frontotemporal dementia.
Shibley ... years. There was no family history of dementia. ...
Reducing the Risk of Dementia R Peila, LR White, K Masaki, H Petrovitch, LJ … - Stroke - Am Heart Assoc ... http://stroke.ahajournals.org located on the World Wide Web at: The online ... of treatment
was lower compared to NTH (HR for dementia 0.40; 95% CI, 0.22 to 0.75 ... -
Source: Google Scholar
FDA Approves the First Treatment for Dementia of Parkinson’s Disease
The Food and Drug Administration (FDA) today approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia (chronic loss or impairment of intellectual capacity) associated with Parkinson's disease, a disorder of the central nervous system. Exelon was previously approved for the treatment of mild to moderate dementia of the Alzheimer's type.
"It's been recognized for almost a decade that the dementia of patients with Parkinson's disease differs from the dementia of patients with Alzheimer's," said Dr. Steven Galson, Director of FDA's Center for Drug Evaluation and Research, "but until now, there has been no treatment that has been shown to be effective specifically for the dementia associated with Parkinson's Disease. Today's approval of Exelon helps to fill this medical need."
It is estimated that about 0.2 percent to 0.5 percent of people over 65 years of age are affected by Parkinson's dementia and experience such symptoms as impairments in executive function, memory and attention. The approval of Exelon for the treatment of Parkinson's dementia is based on the results of a randomized, placebo-controlled clinical study with 541 patients who showed symptoms of mild to moderate dementia two years or later after their diagnosis for Parkinson's disease. At the end of the 24-week trial, the condition of the Exelon-treated patients, as shown on a scale that measures mental processes, was significantly better than the condition of the patients on placebo.
The use of Exelon has been associated with significant gastrointestinal adverse reactions. In clinical trials, 47 percent of the patients treated with the drug developed nausea, and 26 percent of women and 18 percent of men on high doses of Exelon experienced significant weight loss. Other common adverse events reported by patients on Exelon include vomiting, anorexia, dyspepsia and asthenia (loss of strength). In some patients with Parkinson's disease, treatment with Exelon was associated with a worsening of tremor.
Exelon is manufactured by Novartis Pharmaceutical Corp. in East Hanover, NY.
